Accepted for Publication: July 21, 2021.
Published Online: September 3, 2021. doi:10.1001/jamaneurol.2021.2956
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Al-Shahi Salman R et al. JAMA Neurology.
Corresponding Author: Rustam Al-Shahi Salman, PhD, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH16 4SB, United Kingom (rustam.al-shahi@ed.ac.uk).
Author Contributions: Dr Al-Shahi Salman and Ms Rodriguez had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Al-Shahi Salman, Dennis, Sandercock, Sudlow, Murray, Werring, White.
Acquisition, analysis, or interpretation of data: Al-Shahi Salman, Sandercock, Sudlow, Wardlaw, Whiteley, Murray, Stephen, Rodriguez, Lewis, White.
Drafting of the manuscript: Al-Shahi Salman, Rodriguez.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Murray, Stephen, Rodriguez, Lewis.
Obtained funding: Al-Shahi Salman, Dennis, Sudlow, Whiteley, Murray.
Administrative, technical, or material support: Al-Shahi Salman, Sandercock, Wardlaw, Whiteley, White.
Supervision: Al-Shahi Salman, Dennis, Lewis.
Conflict of Interest Disclosures: Dr Dennis reported receiving grants from the British Heart Foundation during the conduct of the study. Dr Sudlow reported receiving grants from the British Heart Foundation during the conduct of the study. Dr Wardlaw reported receiving grants from the Scottish Funding Council during the conduct of the study and grants from Fondation Leducq, British Heart Foundation, EU H2020, UK Stroke Association, Medical Research Council, and Alzheimer’s Society outside the submitted work. Dr Murray reported receiving grants from the British Heart Foundation during the conduct of the study. Dr Werring reported receiving personal fees from Bayer, Alexion/Portola, Alnylam, and NovoNordisk outside the submitted work. Dr White reported receiving grants from Stryker, Penumbra, Medtronic, and Microvention and personal fees from Microvention outside the submitted work. No other disclosures were reported.
Funding/Support: The study was funded by a special project grant SP/12/2/20422 from the British Heart Foundation. The University of Edinburgh and the Lothian Health Board are cosponsors. This study was also supported by the National Institute for Health Research Clinical Research Network, National Health Service Research Scotland Scottish Stroke Research Network, and National Health Service Research Scotland through grant E131252 from the Edinburgh clinical research facility and National Health Service Lothian Research and Development.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The members of the RESTART Collaboration are listed in Supplement 3.
Meeting Presentation: This paper was presented at ESOC 2021, the 7th European Stroke Conference; September 3, 2021; virtual conference.
Data Sharing Statement: See Supplement 4.
Additional Contributions: Imaging acquisition, processing, and data collection were performed at the Edinburgh Imaging Facility, University of Edinburgh, which is part of the SINAPSE (Scottish Imaging Network: A Platform for Scientific Excellence) collaboration (funded by the Scottish Funding Council and the Chief Scientist Office).We thank the British Heart Foundation for funding the trial, continuing to support it while recruitment was challenging, and granting a no-cost extension to enable us to acquire an extra 2 years of follow-up. We thank all participants, their relatives or caregivers, and their primary care practitioners, outcome event adjudicators, imaging adjudicators, the trial steering committee, and the data monitoring committee. We thank the Edinburgh Clinical Trials Unit staff for their involvement.
1.Béjot
Y , Cordonnier
C , Durier
J , Aboa-Eboulé
C , Rouaud
O , Giroud
M . Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study.
Brain. 2013;136(pt 2):658-664. doi:
10.1093/brain/aws349
PubMedGoogle Scholar 2.O’Donnell
MJ , Chin
SL , Rangarajan
S ,
et al; INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.
Lancet. 2016;388(10046):761-775. doi:
10.1016/S0140-6736(16)30506-2
PubMedGoogle ScholarCrossref 5.Li
L , Poon
MTC , Samarasekera
NE ,
et al. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies.
Lancet Neurol. 2021;20(6):437-447. doi:
10.1016/S1474-4422(21)00075-2
PubMedGoogle ScholarCrossref 7.Chen
Y , Wright
N , Guo
Y ,
et al; China Kadoorie Biobank Collaborative Group. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults.
Lancet Glob Health. 2020;8(4):e580-e590. doi:
10.1016/S2214-109X(20)30069-3
PubMedGoogle ScholarCrossref 8.Baigent
C , Blackwell
L , Collins
R ,
et al; Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Lancet. 2009;373(9678):1849-1860. doi:
10.1016/S0140-6736(09)60503-1
PubMedGoogle Scholar 11.Al-Shahi Salman
R , Murray
GD , Dennis
MS ,
et al. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: statistical analysis plan for a randomised controlled trial.
Trials. 2019;20(1):183. doi:
10.1186/s13063-019-3270-2
PubMedGoogle ScholarCrossref 12.Al-Shahi Salman
R , Dennis
MS , Murray
GD ,
et al; RESTART collaborators. The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.
Trials. 2018;19(1):162. doi:
10.1186/s13063-018-2542-6
PubMedGoogle ScholarCrossref 15.Al-Shahi Salman
R , Minks
DP , Mitra
D ,
et al; RESTART Collaboration. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial.
Lancet Neurol. 2019;18(7):643-652. doi:
10.1016/S1474-4422(19)30184-X
PubMedGoogle ScholarCrossref 26.Hróbjartsson
A , Thomsen
AS , Emanuelsson
F ,
et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors.
BMJ. 2012;344:e1119. doi:
10.1136/bmj.e1119
PubMedGoogle Scholar 32.González-Pérez
A , Gaist
D , de Abajo
FJ , Sáez
ME , García Rodríguez
LA . Low-dose aspirin after an episode of haemorrhagic stroke is associated with improved survival.
Thromb Haemost. 2017;117(12):2396-2405. doi:
10.1160/TH17-05-0342
PubMedGoogle Scholar 34.Moon
JY , Lee
JG , Kim
JH . Antiplatelet therapy after intracerebral hemorrhage and subsequent clinical events: a 12-year South Korean Cohort Study.
Eur Neurol. 2021;84(3):183-191. doi:
10.1159/000514552
PubMedGoogle ScholarCrossref 36.Shoamanesh
A , Patrice Lindsay
M , Castellucci
LA ,
et al Canadian stroke best practice recommendations:
Management of Spontaneous Intracerebral Hemorrhage, 7th Edition Update 2020.
Int J Stroke. 202;16(3):321-341. doi:
10.1177/1747493020968424 38.Cheng
B , Li
J , Peng
L ,
et al. Efficacy and safety of restarting antiplatelet therapy for patients with spontaneous intracranial haemorrhage: a systematic review and meta-analysis.
J Clin Pharm Ther. 2021;46(4):957-965. doi:
10.1111/jcpt.13377
PubMedGoogle ScholarCrossref 39.Girotra
T , Feng
W . Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): are neurologists feeling more comfortable to RESTART antiplatelet?
Ann Transl Med. 2019;7(suppl 6):S214. doi:
10.21037/atm.2019.08.84
PubMedGoogle ScholarCrossref 41.Li
L , Geraghty
OC , Mehta
Z , Rothwell
PM ; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.
Lancet. 2017;390(10093):490-499. doi:
10.1016/S0140-6736(17)30770-5
PubMedGoogle ScholarCrossref